|
1
|
Schor NF: Neuroblastoma as a
neurobiological disease. J Neurooncol. 41:159–166. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maris JM: Recent advances in
neuroblastoma. N Engl J Med. 362:2202–2211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gustafson WC and Matthay KK: Progress
towards personalized therapeutics: biologic- and risk-directed
therapy for neuroblastoma. Expert Rev Neurother. 11:1411–1423.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Isaacs H Jr: Fetal and neonatal
neuroblastoma: retrospective review of 271 cases. Fetal Pediatr
Pathol. 26:177–184. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maris JM, Hogarty MD, Bagatell R and Cohn
SL: Neuroblastoma. Lancet. 369:2106–2120. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Øra I and Eggert A: Progress in treatment
and risk stratification of neuroblastoma: impact on future clinical
and basic research. Semin Cancer Biol. 21:217–228. 2011.PubMed/NCBI
|
|
7
|
Jiang H, Lin JJ, Su ZZ, Goldstein NI and
Fisher PB: Subtraction hybridization identifies a novel melanoma
differentiation associated gene, mda-7, modulated during human
melanoma differentiation, growth and progression. Oncogene.
11:2477–2486. 1995.
|
|
8
|
Dent P, Yacoub A, Hamed HA, et al: The
development of MDA-7/IL-24 as a cancer therapeutic. Pharmacol Ther.
128:375–384. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pataer A, Chada S, Roth JA, Hunt KK and
Swisher SG: Development of Ad-mda7/IL-24-resistant lung cancer cell
lines. Cancer Biol Ther. 7:103–108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zheng M, Bocangel D, Ramesh R, et al:
Interleukin-24 overcomes temozolomide resistance and enhances cell
death by down-regulation of O6-methylguanine-DNA
methyltransferase in human melanoma cells. Mol Cancer Ther.
7:3842–3851. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lebedeva IV, Su ZZ, Vozhilla N, et al:
Mechanism of in vitro pancreatic cancer cell growth inhibition by
melanoma differentiation-associated gene-7/interleukin-24 and
perillyl alcohol. Cancer Res. 68:7439–7447. 2008. View Article : Google Scholar
|
|
12
|
Park MA, Yacoub A, Sarkar D, et al:
PERK-dependent regulation of MDA-7/IL-24-induced autophagy in
primary human glioma cells. Autophagy. 4:513–515. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yan S, Zhang H, Xie Y, et al: Recombinant
human interleukin-24 suppresses gastric carcinoma cell growth in
vitro and in vivo. Cancer Invest. 28:85–93. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu J, Sheng W, Xie Y, et al: The in vitro
and in vivo antitumor activity of adenovirus-mediated
interleukin-24 expression for laryngocarcinoma. Cancer Biother
Radiopharm. 25:29–38. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang H, Su ZZ, Lin JJ, Goldstein NI,
Young CS and Fisher PB: The melanoma differentiation associated
gene mda-7 suppresses cancer cell growth. Proc Natl Acad Sci
USA. 93:9160–9165. 1996. View Article : Google Scholar
|
|
16
|
Lebedeva IV, Su ZZ, Chang Y, Kitada S,
Reed JC and Fisher PB: The cancer growth suppressing gene
mda-7 induces apoptosis selectively in human melanoma cells.
Oncogene. 21:708–718. 2002.PubMed/NCBI
|
|
17
|
Su ZZ, Lebedeva IV, Sarkar D, et al:
Melanoma differentiation associated gene-7, mda-7/IL-24,
selectively induces growth suppression, apoptosis and
radiosensitization in malignant gliomas in a p53-independent
manner. Oncogene. 22:1164–1180. 2003.PubMed/NCBI
|
|
18
|
Zhuo B, Wang R, Yin Y, et al: Adenovirus
arming human IL-24 inhibits neuroblastoma cell proliferation in
vitro and xenograft tumor growth in vivo. Tumour Biol.
34:2419–2426. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ramesh R, Ito I, Gopalan B, Saito Y,
Mhashilkar AM and Chada S: Ectopic production of MDA-7/IL-24
inhibits invasion and migration of human lung cancer cells. Mol
Ther. 9:510–518. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fisher PB, Sarkar D, Lebedeva IV, et al:
Melanoma differentiation associated gene-7/interleukin-24
(mda-7/IL-24): novel gene therapeutic for metastatic
melanoma. Toxicol Appl Pharmacol. 224:300–307. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fujioka T, Takebayashi Y, Kihana T, et al:
Expression of E-cadherin and β-catenin in primary and peritoneal
metastatic ovarian carcinoma. Oncol Rep. 8:249–255. 2001.
|
|
22
|
Hugh TJ, Dillon SA, O’Dowd G, et al:
β-catenin expression in primary and metastatic colorectal
carcinoma. Int J Cancer. 82:504–511. 1999.
|
|
23
|
Wang F, Nohara K, Olivera A, Thompson EW
and Spiegel S: Involvement of focal adhesion kinase in inhibition
of motility of human breast cancer cells by sphingosine
1-phosphate. Exp Cell Res. 247:17–28. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Neudauer CL and McCarthy JB: Insulin-like
growth factor I-stimulated melanoma cell migration requires
phosphoinositide 3-kinase but not extracellular-regulated kinase
activation. Exp Cell Res. 286:128–137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Goncharova EA, Ammit AJ, Irani C, et al:
PI3K is required for proliferation and migration of human pulmonary
vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol.
283:L354–L363. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kadri Z, Petitfrère E, Boudot C, et al:
Erythropoietin induction of tissue inhibitors of
metalloproteinase-1 expression and secretion is mediated by
mitogen-activated protein kinase and phosphatidylinositol 3-kinase
pathways. Cell Growth Differ. 11:573–580. 2000.PubMed/NCBI
|
|
27
|
Lakka SS, Jasti SL, Kyritsis AP, et al:
Regulation of MMP-9 (type IV collagenase) production and
invasiveness in gliomas by the extracellular signal-regulated
kinase and jun amino-terminal kinase signaling cascades. Clin Exp
Metastasis. 18:245–252. 2000. View Article : Google Scholar
|
|
28
|
Ellerbroek SM, Halbleib JM, Benavidez M,
et al: Phosphatidylinositol 3-kinase activity in epidermal growth
factor-stimulated matrix metalloproteinase-9 production and cell
surface association. Cancer Res. 61:1855–1861. 2001.
|
|
29
|
Goldfarb RH and Liotta LA: Proteolytic
enzymes in cancer invasion and metastasis. Semin Thromb Hemost.
12:294–307. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Matrisian LM: The matrix-degrading
metalloproteinases. Bioessays. 14:455–463. 1992. View Article : Google Scholar
|
|
31
|
Shapiro SD: Matrix metalloproteinase
degradation of extracellular matrix: biological consequences. Curr
Opin Cell Biol. 10:602–608. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pritchard SC, Nicolson MC, Lloret C, et
al: Expression of matrix metalloproteinases 1, 2, 9 and their
tissue inhibitors in stage II non-small cell lung cancer:
Implications for MMP inhibition therapy. Oncol Rep. 8:421–424.
2001.PubMed/NCBI
|
|
33
|
Nakopoulou L, Tsirmpa I, Alexandrou P, et
al: MMP-2 protein in invasive breast cancer and the impact of
MMP-2/TIMP-2 phenotype on overall survival. Breast Cancer Res
Treat. 77:145–155. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lu HF, Lai KC, Hsu SC, et al: Involvement
of matrix metalloproteinases on the inhibition of cells invasion
and migration by emodin in human neuroblastoma SH-SY5Y cells.
Neurochem Res. 34:1575–1583. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ribatti D, Surico G, Vacca A, et al:
Angiogenesis extent and expression of matrix metalloproteinase-2
and -9 correlate with progression in human neuroblastoma. Life Sci.
68:1161–1168. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ara T, Fukuzawa M, Kusafuka T, et al:
Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in
neuroblastoma: association with tumor progression and clinical
outcome. J Pediatr Surg. 33:1272–1278. 1998. View Article : Google Scholar : PubMed/NCBI
|
